ABSTRACT

AN EFFICACY TRIAL OF RECOMBINANT HEPATITIS E (rHEV) VACCINE IN THE ROYAL NEPALESE ARMY.

Mrigendra P. Shrestha FRCP (Edin), Robert McNair Scott, MD, Walter Reed / AFRIMS Research Unit-Nepal (WARUN) a Field Station of the Armed Forces Research Institute of the Medical Sciences (AFRIMS), in Bangkok Thailand and BG Krishna Narsingh Rayamaiji, BG Gautam Ranna Shyakya, BG Karna Bahadur Chand, BG Gyan Bahadur Thapa, BG( Ret) Khagendra Bahadur Shrestha, BG(Ret) Laxmi Ram Malla, BG(Ret) Durga Man Joshi, COL Manoj Prasad Bhattacharya, COL Ramesh Bahadur Basnet, COL Swasti Bajracharya, COL Prakash Raj Pandey, LTC Kishore Jung Rana, LTC Rishi Khatri, LTC Y. Bista, LTC Narbada Thapa of the Shree Birendra Hospital, Chhauni, Kathmandu, Nepal

In the 2000 and 2001 issues of the MJSBH, K.B. Shrestha1 and D.M. Joshi, et al2 present reviews of hepatitis E virus (HEV), covering the clinical illness, epidemiology, prevention of infection and societal and socioeconomic impact on the people of Nepal and on the Royal Nepalese Army (RNA). Jaundice due to hepatitis E deprives the RNA of manpower and costs in the neighborhood of NRps 5,000,000 every year1. In an attempt to ultimately relieve this military and economic burden, the RNA is currently testing a candidate HEV vaccine in collaboration with the Walter Reed/AFRIMS Research Unit-Nepal (WARUN) field unit of the Armed Forces Research Institute of the Medical Sciences, a subsidiary of the Walter Reed Army Institute of the Medical Sciences. To date the trial is ongoing.